OncoMatch/Clinical Trials/NCT06017284
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
Is NCT06017284 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Thalidomide and Nab paclitaxel for pancreatic cancer stage iv.
Treatment: Thalidomide · Nab paclitaxel · Gemcitabine — The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-tumor therapy
Patients who have received any form of anti-tumor therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify